HU201906B
(en)
*
|
1987-03-04 |
1991-01-28 |
Sandoz Ag |
Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
|
JP3598116B2
(ja)
*
|
1994-04-15 |
2004-12-08 |
雅臣 伊豫 |
遅発性ジスキネジアの治療用医薬組成物とその利用
|
US6251938B1
(en)
|
1996-12-18 |
2001-06-26 |
Teva Pharmaceutical Industries, Ltd., |
Phenylethylamine derivatives
|
DE69725467T2
(de)
*
|
1996-12-18 |
2004-07-22 |
Teva Pharmaceutical Industries Ltd. |
Phenylethylamin-derivate
|
IL130528A
(en)
|
1996-12-18 |
2004-12-15 |
Teva Pharma |
Aminoindan derivatives, pharmaceutical compositions comprising them and uses thereof
|
US6316023B1
(en)
*
|
1998-01-12 |
2001-11-13 |
Novartis Ag |
TTS containing an antioxidant
|
GB9800526D0
(en)
*
|
1998-01-12 |
1998-03-11 |
Ciba Geigy Ag |
Organic compounds
|
US6218383B1
(en)
|
1998-08-07 |
2001-04-17 |
Targacept, Inc. |
Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
|
BR9914251A
(pt)
|
1998-10-01 |
2001-06-19 |
Novartis Ag |
Formulações orais de liberação sustentada
|
US20040209849A1
(en)
*
|
1998-11-27 |
2004-10-21 |
Sanochemia Pharmazeutika Aktiengesellschaft |
Use of effectors of the central cholinergic nervous system for treatment of delirium
|
AU2354400A
(en)
*
|
1998-12-11 |
2000-06-26 |
Bonnie Davis |
Use of acetylcholinesterase inhibitors on the modulation of the hypothalamic-pituitary-gonadal axis
|
GB9923045D0
(en)
*
|
1999-09-29 |
1999-12-01 |
Novartis Ag |
New oral formulations
|
US6534541B1
(en)
|
1999-10-19 |
2003-03-18 |
Novartis Ag |
Treatment of ocular disorders
|
AU5702201A
(en)
*
|
2000-04-13 |
2001-10-30 |
Mayo Foundation |
Abeta<sub>42</sub> lowering agents
|
US20040010038A1
(en)
*
|
2002-02-27 |
2004-01-15 |
Eran Blaugrund |
Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
|
CZ293014B6
(cs)
|
2002-10-24 |
2004-01-14 |
Léčiva, A.S. |
Způsob výroby (-)-(S)-3-[1-(dimethylamino)ethyl]fenyl-N-ethyl-N-methylkarbamátu
|
EP1556019A2
(en)
*
|
2002-10-24 |
2005-07-27 |
Merz Pharma GmbH & Co. KGaA |
Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
|
WO2004071431A2
(en)
*
|
2003-02-05 |
2004-08-26 |
Myriad Genetics, Inc. |
Method and composition for treating neurodegenerative disorders
|
US7521481B2
(en)
|
2003-02-27 |
2009-04-21 |
Mclaurin Joanne |
Methods of preventing, treating and diagnosing disorders of protein aggregation
|
AU2004311577A1
(en)
*
|
2003-07-11 |
2005-07-21 |
Myriad Genetics, Inc. |
Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
|
EP1689704A2
(en)
*
|
2003-10-21 |
2006-08-16 |
CoLucid Pharmaceuticals, Inc. |
Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
|
GB2409453A
(en)
*
|
2003-12-24 |
2005-06-29 |
Generics |
Process for the preparation of aminoalkyl phenylcarbamates
|
WO2006001877A2
(en)
*
|
2004-04-13 |
2006-01-05 |
Myriad Genetics, Inc. |
Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
|
US20050252144A1
(en)
*
|
2004-04-29 |
2005-11-17 |
Macdonald Robert A |
Veneers for walls, retaining walls and the like
|
WO2006004201A1
(ja)
*
|
2004-07-01 |
2006-01-12 |
Eisai R & D Management Co., Ltd. |
神経再生促進剤
|
BRPI0514303A
(pt)
*
|
2004-08-11 |
2008-06-10 |
Myriad Genetics Inc |
composição farmacêutica e método para tratar distúrbios neurodegenerativos
|
WO2006020850A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
WO2006020852A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
JP4954886B2
(ja)
*
|
2004-11-08 |
2012-06-20 |
エムキュア ファーマシューティカルズ リミテッド |
(s)−3−[(1−ジメチルアミノ)エチル]−フェニル−n−エチル−n−メチル−カルバミン酸の効率的製造方法
|
GB0507298D0
(en)
|
2005-04-11 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
CA2615063A1
(en)
*
|
2005-07-22 |
2007-02-01 |
Myriad Genetics, Inc. |
High drug load formulations and dosage forms
|
ES2267399B1
(es)
|
2005-08-04 |
2008-02-01 |
Ragactives, S.L. |
Procedimiento para la obtencion de carbamatos de fenilo.
|
ATE546202T1
(de)
|
2005-09-15 |
2012-03-15 |
Sony Computer Entertainment Inc |
Kabelloser videospielcontroller und verfahren zum betreiben des kabellosen videospielcontrollers
|
TWI389709B
(zh)
|
2005-12-01 |
2013-03-21 |
Novartis Ag |
經皮治療系統
|
AU2006326642B2
(en)
*
|
2005-12-09 |
2012-05-03 |
Technion Research And Development Foundation Ltd. |
Use of low-dose ladostigil for neuroprotection
|
TW200744576A
(en)
*
|
2006-02-24 |
2007-12-16 |
Teva Pharma |
Propargylated aminoindans, processes for preparation, and uses thereof
|
US7767843B2
(en)
*
|
2006-03-02 |
2010-08-03 |
Apotex Pharmachem Inc. |
Process for the preparation of phenylcarbamates
|
US20080033045A1
(en)
*
|
2006-07-07 |
2008-02-07 |
Myriad Genetics, Incorporated |
Treatment of psychiatric disorders
|
EP2054373B1
(en)
*
|
2006-08-17 |
2010-06-30 |
Alembic Limited |
Improved process for the preparation of rivastigmine
|
WO2008037433A1
(en)
|
2006-09-29 |
2008-04-03 |
Synthon B.V. |
Process for making aminoalkylphenyl carbamates and intermediates therefor
|
EP2420235A1
(en)
|
2006-10-27 |
2012-02-22 |
Medivation Neurology, Inc. |
Methods and combination therapies for treating alzheimer's disease
|
EP1942100A1
(en)
*
|
2007-01-04 |
2008-07-09 |
Krka Tovarna Zdravil, D.D., Novo Mesto |
Amorphous and crystalline forms of rivastigmine hydrogentartrate
|
CA2677241A1
(en)
*
|
2007-02-02 |
2008-08-14 |
Colucid Pharmaceuticals, Inc. |
Compounds that inhibit cholinesterase
|
US8013181B2
(en)
*
|
2007-04-10 |
2011-09-06 |
Dr. Reddy's Laboratories Limited |
Preparation of rivastigmine and its salts
|
WO2008124969A1
(fr)
*
|
2007-04-16 |
2008-10-23 |
Topharman Shanghai Co., Ltd. |
Méthode de préparation de rivastigmine et de ses intermédiaires
|
US7884121B2
(en)
*
|
2007-06-11 |
2011-02-08 |
Apotex Pharmachem Inc. |
Process for the preparation of phenylcarbamates
|
CN101795683A
(zh)
*
|
2007-07-18 |
2010-08-04 |
科露西德医药品公司 |
用于促进警醒症的方法
|
US8593728B2
(en)
*
|
2009-02-19 |
2013-11-26 |
Toyota Motor Engineering & Manufacturing North America, Inc. |
Multilayer photonic structures
|
US20090082436A1
(en)
*
|
2007-09-26 |
2009-03-26 |
Protia, Llc |
Deuterium-enriched rivastigmine
|
EP2233465B1
(en)
*
|
2008-01-10 |
2017-06-28 |
Shanghai Institute of Pharmaceutical Industry |
Preparation method of rivastigmine, its intermediates and preparation method of the intermediates
|
WO2010023535A1
(en)
|
2008-08-25 |
2010-03-04 |
Jubilant Organosys Limited |
A process for producing (s)-3-[(1-dimethylamino)ethyl] phenyl-n-ethyl-n-methyl-carbamate via novel intermediates
|
US20100087768A1
(en)
*
|
2008-10-02 |
2010-04-08 |
Forlano Paula |
Transdermal drug delivery system for liquid active ingredient
|
GB0823554D0
(en)
*
|
2008-12-24 |
2009-01-28 |
Novartis Ag |
Process for the preparation of optically active compounds using transfer hydrogenation
|
CN101823970B
(zh)
*
|
2009-03-03 |
2013-05-08 |
江苏恩华药业股份有限公司 |
卡巴拉汀及其中间体的合成方法
|
US10076502B2
(en)
|
2009-12-22 |
2018-09-18 |
Luye Pharma Ag |
Transdermal therapeutic system for administering rivastigmine or derivatives thereof
|
ES2670227T3
(es)
|
2009-12-22 |
2018-05-29 |
Luye Pharma Ag |
Sistema terapéutico transdérmico para la administración de rivastigmina o sus derivados
|
ES2363395B1
(es)
*
|
2010-01-20 |
2012-02-23 |
Farmalider, S.A. |
Composición farmacéutica l�?quida de rivastigmina o de una de sus sales de adición de �?cido para la administración por v�?a oral.
|
EP2533645B1
(en)
*
|
2010-02-09 |
2016-07-27 |
The Johns Hopkins University |
Methods and compositions for improving cognitive function
|
MA34084B1
(fr)
|
2010-03-29 |
2013-03-05 |
Novartis Ag |
Composition comprenant le peptide amyloïde bêta 1-6 couplé à une particule de type virus et un adjuvant
|
WO2011151669A1
(en)
|
2010-06-02 |
2011-12-08 |
Jubilant Life Sciences Limited |
Process for producing enantiomerically enriched isomer of 3-(1-aminoethyl) phenyl derivative and employing the same to produce rivastigmine or its pharmaceutically acceptable salt
|
WO2011151359A1
(en)
|
2010-06-02 |
2011-12-08 |
Noscira, S.A. |
Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
|
US8852900B2
(en)
|
2010-06-17 |
2014-10-07 |
Codexis, Inc. |
Biocatalysts and methods for the synthesis of (S)-3-(1-aminoethyl)-phenol
|
CA2818025A1
(en)
|
2010-11-15 |
2012-05-24 |
Agenebio, Inc. |
Pyridazine derivatives, compositions and methods for treating cognitive impairment
|
PT2468274E
(pt)
|
2010-12-14 |
2015-09-21 |
Acino Ag |
Sistema terapêutico transdérmico para a administração de uma substância ativa
|
CN102786441B
(zh)
|
2011-05-18 |
2013-11-13 |
浙江海正药业股份有限公司 |
利凡斯的明的制备方法、其中间体以及中间体的制备方法
|
WO2012161489A2
(ko)
|
2011-05-20 |
2012-11-29 |
에스케이케미칼 주식회사 |
리바스티그민 함유 패취
|
AR082640A1
(es)
*
|
2011-08-25 |
2012-12-19 |
Amarin Technologies S A |
Un dispositivo para la administracion transdermal de compuestos alcalinos susceptibles a la degradacion en su forma no salificada
|
US9333182B2
(en)
|
2011-08-31 |
2016-05-10 |
Sekisui Medical Co., Ltd. |
Adhesive patch
|
CN103073456B
(zh)
*
|
2011-10-26 |
2014-03-19 |
连云港润众制药有限公司 |
重酒石酸卡巴拉汀中间体的制备方法
|
EP2594261A1
(en)
|
2011-11-18 |
2013-05-22 |
Labtec GmbH |
Composition for transdermal administration of rivastigmine
|
WO2013142339A1
(en)
|
2012-03-23 |
2013-09-26 |
Novartis Ag |
Transdermal therapeutic system and method
|
ES2449215B1
(es)
*
|
2012-09-17 |
2014-07-14 |
Galenicum Health S.L. |
Solución oral de (S)-3-[1-(dimetilamino)etil]fenil N-etil-N-metilcarbamato
|
KR20140038237A
(ko)
|
2012-09-20 |
2014-03-28 |
에스케이케미칼주식회사 |
리바스티그민의 안정성이 개선된 의약품
|
EP2919788A4
(en)
|
2012-11-14 |
2016-05-25 |
Univ Johns Hopkins |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
|
CN103896787A
(zh)
*
|
2012-12-26 |
2014-07-02 |
江苏康倍得药业有限公司 |
一种卡巴拉汀前体[1-(3-甲氧基苯基)乙基]二甲胺的制备方法
|
WO2014111790A2
(en)
|
2013-01-15 |
2014-07-24 |
Zydus Technologies Limited |
Stable transdermal pharmaceutical drug delivery system comprising rivastigmine
|
EP2968237A4
(en)
|
2013-03-15 |
2016-08-31 |
Univ Johns Hopkins |
METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
|
DK2968220T3
(da)
|
2013-03-15 |
2021-06-14 |
Agenebio Inc |
Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion
|
CN103319374B
(zh)
*
|
2013-06-09 |
2015-04-22 |
无锡佰翱得生物科学有限公司 |
一种(s)-卡巴拉汀的不对称合成方法
|
TW201540301A
(zh)
|
2013-08-16 |
2015-11-01 |
Takeda Gmbh |
以pde4抑制劑治療認知損傷
|
EP3083569B1
(en)
|
2013-12-20 |
2022-01-26 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
BR112017025031B1
(pt)
|
2015-05-22 |
2023-03-21 |
Agenebio, Inc |
Composições farmacêuticas de liberação prolongada de levetiracetam
|
WO2016205739A1
(en)
|
2015-06-19 |
2016-12-22 |
Belew Mekonnen |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
US20180170941A1
(en)
|
2016-12-19 |
2018-06-21 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
BR112019012821A2
(pt)
|
2016-12-19 |
2019-11-26 |
Agenebio Inc |
derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
|
CN112601749B
(zh)
|
2018-06-19 |
2024-03-26 |
艾吉因生物股份有限公司 |
用于治疗认知损害的苯并二氮杂环庚三烯衍生物,组合物和方法
|
KR20200035359A
(ko)
|
2018-09-26 |
2020-04-03 |
캐딜라 파마슈티클즈 리미티드 |
리바스티그민 제조용 중간체의 합성
|
WO2024039886A1
(en)
|
2022-08-19 |
2024-02-22 |
Agenebio, Inc. |
Benzazepine derivatives, compositions, and methods for treating cognitive impairment
|